Vapogenix Overview

  • Founded
  • 2007
Founded
  • Status
  • Private
  • Employees
  • 4
Employees
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $1.5M
Latest Deal Amount
  • Investors
  • 7

Vapogenix General Information

Description

Developer of non-opioid medications designed to alleviate pain associated with venipuncture, venous cannulation and minor dermatological procedures. The company's medications are based on formulated volatile anesthetics and used on hospitalized children prior to venous access procedures and by dermatologists to prevent pain associated with both aesthetic and medical procedures, enabling them to save time and stress waiting for current products to work and improve the productivity of hospital staff and dermatology practices.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
  • 8285 El Rio Street
  • Suite 170
  • Houston, TX 77054
  • United States
+1 (713) 000-0000

Vapogenix Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vapogenix Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 11-Nov-2020 $1.5M 000.00 Completed Clinical Trials - General
6. Later Stage VC (Series C) 11-Jan-2018 00.000 000.00 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series C) 08-Dec-2016 00.00 000.00 0000 Completed Clinical Trials - General
4. Later Stage VC (Series B) 23-Dec-2014 00.00 00.00 000.00 Completed Clinical Trials - General
3. Later Stage VC (Series B) 03-Jul-2013 000 00.00 000.00 Completed Clinical Trials - General
2. Grant 03-Jul-2013 $2M $3.3M Completed Clinical Trials - General
1. Later Stage VC (Series A) 25-Feb-2013 $3.3M $3.3M 00.00 Completed Clinical Trials - General
To view Vapogenix’s complete valuation and funding history, request access »

Vapogenix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C 0,000,000 00.000000 00 00.00 00.0 00 00.00 00.00
Series B 0,000,000 00.000000 00 00.0 00.0 00 00.0 00.000
Series A 2,289,003 $0.001000 6% $1.44 $1.44 1x $1.41 14.23%
To view Vapogenix’s complete cap table history, request access »

Vapogenix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of non-opioid medications designed to alleviate pain associated with venipuncture, venous cannulation and mino
Drug Discovery
Houston, TX
4 As of 2020
000.00
0000000000 000.00

0000000

Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo con
000000000000000
Concord, MA
00 As of 0000
00000
0000000000 0 00000

00000000

olor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore mag
0000 000000000
Plymouth, MN
0 As of 0000
000
0000000000 000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vapogenix Competitors (2)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tremeau Pharmaceuticals Venture Capital-Backed Concord, MA 00 00000 0000000000 0 00000
0000000000 Angel-Backed Plymouth, MN 0 000 0000000000 000
You’re viewing 2 of 2 competitors. Get the full list »

Vapogenix Executive Team (8)

Name Title Board Seat Contact Info
Heather Giles Ph.D Chief Executive Officer, Board Member, President & Chief Scientific Officer
Clarice Motter Chief Financial Officer
Danguole Altman Co-Founder & Advisor
Phillip Phan MD Co-Founder, Scientific Co-Founder & Co-Chairman of Scientific Advisory Board
Allen Burton MD Co-Founder, Scientific Co-Founder, & Co-Chairman of Scientific Advisory Board
You’re viewing 5 of 8 executive team members. Get the full list »

Vapogenix Board Members (9)

Name Representing Role Since
Bruce Given MD Self Board Member & Advisor 000 0000
Christopher Jorgensen Self Board Member 000 0000
Clay Heighten MD Self Board Observer 000 0000
George Davitt Self Board Member 000 0000
Marc Loev MD National Spine & Pain Centers Board Member 000 0000
You’re viewing 5 of 9 board members. Get the full list »

Vapogenix Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vapogenix Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
National Institutes of Health Government 000 0000 000000 0
Kli Capital Venture Capital Minority 000 0000 000000 0
National Spine & Pain Centers PE-Backed Company Minority 000 0000 000000 0
Pamoja Capital PE/Buyout Minority 000 0000 000000 0
Texas Emerging Technology Fund Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 7 investors. Get the full list »